The HB22.7 Anti-CD22 Monoclonal Antibody Is an Effective Platform for CD22-Targeted Antibody Drug Conjugates for Treatment of Lymphoma and Acute Lymphoblastic Leukemia

被引：1
|
作者：
Boyle, Soames F. [1 ]
Kato, Jason [2 ]
O'Donnell, Robert [2 ]
Tuscano, Joseph [3 ]
机构：
[1] UC Davis Sch Med, Div Hematol Oncol, Sacramento, CA USA
[2] Univ Calif Davis, Div Hematol & Oncol, Sacramento, CA USA
[3] UC Davis Canc Ctr, Sacramento, CA USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1653.1653
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1653
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7
    Kong, YanGuo
    Barisone, Gustavo A.
    Abuhay, Mastewal
    O'Donnell, Robert T.
    Buksh, Zaneb
    Yousefian, Faraz
    Tuscano, Joseph M.
    LEUKEMIA RESEARCH, 2014, 38 (11) : 1320 - 1326
  • [2] Treatment of non-Hodgkin’s lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy
    Robert T. O’Donnell
    David Pearson
    Hayes C. McKnight
    Ya Peng Ma
    Joseph M. Tuscano
    Cancer Immunology, Immunotherapy, 2009, 58 : 1715 - 1722
  • [3] Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy
    O'Donnell, Robert T.
    Pearson, David
    McKnight, Hayes C.
    Ma, Ya Peng
    Tuscano, Joseph M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (10) : 1715 - 1722
  • [4] Sodium orthovanadate (NaV) effects CD22 expression, intracellular signaling, and lymphomacidal activity of the HB22.7 anti-CD22 monoclonal antibody.
    O'Donnell, RT
    Pearson, D
    McKnight, H
    Tedder, TF
    Tuscano, JM
    BLOOD, 2005, 106 (11) : 428A - 428A
  • [5] The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner
    Shiloh M Martin
    Eric Churchill
    Hayes McKnight
    Christopher M Mahaffey
    Yunpeng Ma
    Robert T O'Donnell
    Joseph M Tuscano
    Journal of Hematology & Oncology, 4
  • [6] The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner
    Martin, Shiloh M.
    Churchill, Eric
    McKnight, Hayes
    Mahaffey, Christopher M.
    Ma, Yunpeng
    O'Donnell, Robert T.
    Tuscano, Joseph M.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [7] Non-clinical pharmacology of anti-CD22 antibody drug conjugates
    Xie, Dong
    Baudys, Jakijb
    Chan, Pam
    Deng, Rong
    Dere, Randy
    Ebens, Allen
    Fielder, Paul
    Fuh, Franklin
    Fuji, Reina
    Gray, Alane
    Huang, Catherine
    Jumbe, Shasha
    Makeever, Kathleen
    Saad, Ola
    Stephah, Jean-Thilippe
    Tibbitts, Jay
    Williams, Mama
    Yu, Shang-Fan
    Prabhu, Saileta
    BLOOD, 2007, 110 (11) : 698A - 698A
  • [8] Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugates
    Satake, Noriko
    Duong, Connie
    Oestergaard, Michael
    Yoshida, Sakiko
    Chen, Cathy
    Nolta, Jan A.
    Guo, Shuling
    Seth, Punit
    Nitin, Nitin
    Tuscano, Joseph
    BLOOD, 2014, 124 (21)
  • [9] Pharmacokinetics of anti-CD22 antibody conjugates with uncleavable and cleavable linkers in rat
    Xie, Dong
    Deng, Rong
    Baudys, Jakob
    Chan, Pam
    Dere, Randy
    Ebens, Allen
    Fielder, Paul
    Fuji, Reina
    Gray, Alane
    Hung, Catherine
    Iyer, Suhas
    McKeever, Kathleen
    Kenrick, Margaret
    Leach, Will
    Polson, Andrew
    Saad, Ola
    Stephan, Jean-Philippe
    Shen, Ben Quan
    Tibbitts, Jay
    Yu, Shang-Fan
    Prabhu, Saileta
    BLOOD, 2007, 110 (11) : 697A - 697A
  • [10] CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia
    Hoelzer, Dieter
    CANCER, 2013, 119 (15) : 2671 - 2674
12345